FRESNO, Calif., Feb. 26, 2016 -- A jury in a civil trial in Fresno Superior Court has decided that a local doctor, Michael J. Moffett, should pay more than $1.4 million to California Cancer Associates for Research & Excellence, Inc. (cCARE). cCARE had contended that Moffett misused funds as CEO and attempted to damage cCARE by negotiating a secret deal with a competitive medical practice while still an employee/shareholder.
Moffett resigned from cCARE in 2013 and later filed a lawsuit claiming that he was forced out of the medical practice. In response, cCARE claimed that Moffett paid himself improper compensation and expense reimbursements and later tried to cover his actions by destroying records.
The jury awarded $1,246,559 in damages to cCARE against Moffett, plus another $200,000 in punitive damages, finding that he and Maria Madrigal Shaffer, his chief administrator, “acted with malice, oppression and fraud in conscious disregard of [cCARE’s] rights.”
The jury also found that Moffett and Shaffer had committed “fraud, breach of fiduciary duty and/or breach of duty of loyalty” and awarded cCARE an additional $25,000 in damages and $10,000 in punitive damages against Shaffer.
The jury verdict follows a judge’s earlier decision that cCARE owed Moffett more than $1 million for his stock ownership in cCARE and for unpaid deferred compensation. However, in seven points of contention listed in the verdict, the judge gave five to the jury to decide and ruled on two himself. While the judge found in Moffett’s favor in the two, the jury decided for cCARE in all five of the remaining issues.
“We’re obviously delighted that after the jury heard all the evidence, they ruled in our favor on every one of the issues which were left to them to decide,” said Troy Simon, current CEO of cCARE. “This result validates our primary value of putting the care of our patients over the individual interests of any one person in our organization.”
Moffett initiated action by filing a lawsuit against cCARE, who responded by filing a counter-claim. The trial started the last week of January and concluded February 23.
About cCARE
California Cancer Associates for Research and Excellence, cCARE, is the largest full-service private oncology practice in California. cCARE delivers the highest quality medical oncology, chemotherapy and radiation treatments, supplemented by a large research and clinical trials program. With nine clinic locations in the San Diego and Fresno areas, patients receive thorough, compassionate and convenient treatment no matter where they call home. For more information visit www.ccare.com.
Media Contact: Paul Kellogg PR Director (303) 552-6510 [email protected]


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Instagram Outage Disrupts Thousands of U.S. Users
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



